Nucleic Acids Research Advance Access published online on September 12, 2008
Nucleic Acids Research, doi:10.1093/nar/gkn560
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Genome Integrity, Repair, and Replication |
The SET and transposase domain protein Metnase enhances chromosome decatenation: regulation by automethylation
1Division of Hematology–Oncology, Cancer Research and Treatment Center, Department of Medicine, University of New Mexico Health Science Center, Albuquerque, NM 87131, 2Department of Biochemistry and Molecular Biology, Indiana University School of Medicine, Indianapolis, IN 46202, 3Department of Biochemistry and Molecular Biology, University of New Mexico School of Medicine and 4Department of Molecular Genetics and Microbiology, University of New Mexico School of Medicine, Albuquerque, NM 87131, USA
To whom correspondence should be addressed. Tel: +1 505 272 5837; Fax: +1 505 272 5865; Email: rhromas{at}salud.unm.edu
Received May 16, 2008. Revised August 18, 2008. Accepted August 19, 2008.
Metnase is a human SET and transposase domain protein that methylates histone H3 and promotes DNA double-strand break repair. We now show that Metnase physically interacts and co-localizes with Topoisomerase II
(Topo II
), the key chromosome decatenating enzyme. Metnase promotes progression through decatenation and increases resistance to the Topo II
inhibitors ICRF-193 and VP-16. Purified Metnase greatly enhanced Topo II
decatenation of kinetoplast DNA to relaxed circular forms. Nuclear extracts containing Metnase decatenated kDNA more rapidly than those without Metnase, and neutralizing anti-sera against Metnase reversed that enhancement of decatenation. Metnase automethylates at K485, and the presence of a methyl donor blocked the enhancement of Topo II
decatenation by Metnase, implying an internal regulatory inhibition. Thus, Metnase enhances Topo II
decatenation, and this activity is repressed by automethylation. These results suggest that cancer cells could subvert Metnase to mediate clinically relevant resistance to Topo II
inhibitors.
![]()
CiteULike
Connotea
Del.icio.us What's this?
This article has been cited by other articles:
![]() |
J. Rhodes, A. Amsterdam, T. Sanda, L. A. Moreau, K. McKenna, S. Heinrichs, N. J. Ganem, K. W. Ho, D. S. Neuberg, A. Johnston, et al. Emi1 Maintains Genomic Integrity during Zebrafish Embryogenesis and Cooperates with p53 in Tumor Suppression Mol. Cell. Biol., November 1, 2009; 29(21): 5911 - 5922. [Abstract] [Full Text] [PDF] |
||||
![]() |
C. Claeys Bouuaert and R. Chalmers Transposition of the human Hsmar1 transposon: rate-limiting steps and the importance of the flanking TA dinucleotide in second strand cleavage Nucleic Acids Res., October 25, 2009; (2009) gkp891v1. [Abstract] [Full Text] [PDF] |
||||
![]() |
D. J. Clarke Decatenation: fixing your knots Blood, August 27, 2009; 114(9): 1721 - 1722. [Abstract] [Full Text] [PDF] |
||||
![]() |
J. Wray, E. A. Williamson, S. Sheema, S.-H. Lee, E. Libby, C. L. Willman, J. A. Nickoloff, and R. Hromas Metnase mediates chromosome decatenation in acute leukemia cells Blood, August 27, 2009; 114(9): 1852 - 1858. [Abstract] [Full Text] [PDF] |
||||


